Sebastian Gensior

Overview and Investment Focus Bertelsmann Healthcare Investments (BHI) is a dedicated healthcare venture fund launched in late January 2026 by

What has tiny arms but might revolutionize autoimmune treatment? No, not that T-Rex—this one's all about regulatory T cells, and its reach into immunology is anything but short.

Introduction Arrow declarations have emerged as a distinctive mechanism in patent litigation, particularly within the UK pharmaceutical sector, with significant

Equity kickers—warrants, options, convertible features, or other equity-linked instruments bundled with debt or investment transactions—serve as return enhancers

Recent pharmaceutical royalty financings have increasingly featured "royalty tail" provisions. In a royalty monetization, an originator (typically a

The final week of January 2026 delivered the largest licensing deal of the year so far, a collapsed mega-merger, and

2025-2026 Market Overview: Record Volume Reshapes the Landscape Before diving into the technical intricacies of liens, it is worth pausing

SLR Investment Corp. (NASDAQ: SLRC) is a New York-based business development company externally managed by SLR Capital Partners, a specialty

Executive Summary Mendra, Inc. is a newly launched San Francisco-based biopharmaceutical company targeting high-unmet-need rare diseases. In January 2026, the

The Gulf Cooperation Council (GCC) pharmaceutical industry is undergoing significant structural changes as sovereign wealth funds deploy capital and local